Hybrid red blood cell membrane coated porous silicon nanoparticles functionalized with cancer antigen induce depletion of T cells

Antti Rahikkala, Flavia Fontana, Tomás Bauleth-Ramos, Alexandra Maria Rebelo Correia, Marianna Kemell, Jani Seitsonen, Ermei Mäkilä, Bruno Sarmento, Jarno Salonen, Janne Ruokolainen, Jouni Hirvonen, Hélder A. Santos

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Erythrocyte-based drug delivery systems have been investigated for their biocompatibility, long circulation time, and capability to transport cargo all around the body, thus presenting enormous potential in medical applications. In this study, we investigated hybrid nanoparticles consisting of nano-sized autologous or allogeneic red blood cell (RBC) membranes encapsulating porous silicon nanoparticles (PSi NPs). These NPs were functionalized with a model cancer antigen TRP2, which was either expressed on the surface of the RBCs by a cell membrane-mimicking block copolymer polydimethylsiloxane-b-poly-2-methyl-2-oxazoline, or attached on the PSi NPs, thus hidden within the encapsulation. When in the presence of peripheral blood immune cells, these NPs resulted in apoptotic cell death of T cells, where the NPs having TRP2 within the encapsulation led to a stronger T cell deletion. The deletion of the T cells did not change the relative proportion of CD4+ and cytotoxic CD8+ T cells. Overall, this work shows the combination of nano-sized RBCs, PSi, and antigenic peptides may have use in the treatment of autoimmune diseases.
Original languageEnglish
JournalRSC Advances
Volume10
Issue number58
Pages (from-to)35198-35205
Number of pages8
ISSN2046-2069
DOIs
Publication statusPublished - 23 Sep 2020
MoE publication typeA1 Journal article-refereed

Fields of Science

  • 317 Pharmacy
  • DENDRITIC CELLS
  • SURFACE-CHEMISTRY
  • IMMUNE-RESPONSES
  • IN-VITRO
  • DRUG-DELIVERY
  • RBC MEMBRANES
  • TRP-2
  • TOLERANCE
  • PEPTIDE
  • 116 Chemical sciences
  • 318 Medical biotechnology

Cite this